



**Exhibit List**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated January 18, 2006, concerning a grant of priority review by the FDA for possible new indication for Plavix®.
Exhibit 99.2	Press Release dated January 24, 2006, announcing the receipt of marketing approval in Japan for Plavix®
Exhibit 99.3	Press Release dated January 24, 2006, responding to market rumors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 25, 2006

SANOFI-AVENTIS

By: /s/ Patricia Kodyra  
Name: Patricia Kodyra  
Title: Associate Vice President  
Financial and Securities Law

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated January 18, 2006, concerning a grant of priority review by the FDA for possible new indication for Plavix®.
Exhibit 99.2	Press Release dated January 24, 2006, announcing the receipt of marketing approval in Japan for Plavix®
Exhibit 99.3	Press Release dated January 24, 2006, responding to market rumors.